Natera, Inc. ($NTRA) Stock Forecast: Up 7.5% Today

What is Natera, Inc.?

Natera Inc. (NTRA) is a leading innovative healthcare company specializing in genetic testing and precision medicine. The company has been making significant strides in the oncology and transplant monitoring sectors, with a focus on improving patient outcomes through advanced diagnostic tools.

Why is Natera, Inc. going up?

NTRA stock is up 7.5% on Jun 25, 2026 13:51

• The bullish movement in NTRA stock today can be attributed to the strategic partnership announcement with Eledon Pharmaceuticals for the exclusive use of Natera's Prospera kidney transplant assessment test in a Phase 3 clinical trial. This collaboration not only validates the effectiveness of Natera's technology but also opens up a new avenue for revenue generation and market expansion.
• Additionally, the recent approval of Natera's Signatera MRD test for colorectal cancer in Japan and the NCCN endorsement for its bladder cancer test have further boosted investor confidence in the company's growth potential and market position in the oncology sector.
• The positive market sentiment is also reflected in analysts' Buy/Outperform ratings and raised price targets, indicating a strong outlook for Natera despite its current status as a high-growth but loss-making company. The endorsements and partnerships are likely to drive increased adoption of Natera's tests, leading to potential revenue growth in the near future.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial

Natera and Eledon Therapeutics have announced a strategic partnership for the use of Natera's Prospera™ monitoring in a planned Phase 3 kidney transplant trial. This collaboration will likely focus on improving patient outcomes through advanced monitoring techniques during the trial. The announcement suggests a move towards integrating specialized diagnostic tools into clinical research for transplant patients.

https://www.tradingview.com/news/reuters.com,2026:newsml_TUA7WBQ4V:0-natera-and-eledon-announce-strategic-partnership-for-prospera-monitoring-in-planned-phase-3-kidney-transplant-trial/

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Natera and Eledon Pharmaceuticals have announced a strategic partnership for Natera's Prospera kidney transplant assessment test to be exclusively used in Eledon's planned Phase 3 clinical trial of tegoprubart. This trial aims to prevent organ rejection in kidney transplantation, with enrollment expecting to include approximately 600 kidney transplant recipients globally. The collaboration marks the first time Prospera will be incorporated as a longitudinal surveillance tool in a large-scale therapeutic clinical trial, providing insights into allograft health and the impact of the investigational immunosuppression regimen.

https://uk.finance.yahoo.com/news/natera-eledon-announce-strategic-partnership-110000796.html

[144] Natera, Inc. SEC Filing

This SEC Form 144 filing indicates a proposed sale of 16,530 shares of Natera, Inc. (NTRA) common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $4,132,500. The shares were acquired on June 24, 2026, through a stock option exercise, with payment made in cash. The filing includes standard disclosures required by Rule 144 of the Securities Act of 1933.

https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-40d0b3cd28c0.html

Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer

Natera has received approval from Japan's Ministry of Health, Labour and Welfare for its Signatera molecular residual disease (MRD) test for colorectal cancer, making it the first PMDA-approved MRD test in the country. The company plans to commercially launch Signatera in Japan by the end of 2026, with SRL Inc. leading commercialization. This approval is a significant step in Natera's international oncology expansion, backed by strong clinical evidence from the GALAXY trial, and follows NCCN recognition for its bladder cancer technology.

https://www.benzinga.com/news/health-care/26/06/60080542/natera-secures-landmark-japan-nod-for-signatera-in-colorectal-cancer

Natera Stock Jumps As NCCN Endorses Signatera MRD Test

Natera Inc. stock (NASDAQ: NTRA) jumped over 12% following the National Comprehensive Cancer Network's (NCCN) endorsement of its Signatera MRD test for bladder cancer, giving it a Category 1 recommendation. This validation, along with a recent FDA approval, is expected to significantly increase test adoption and revenue. Analysts from BTIG and RBC Capital have reiterated Buy/Outperform ratings and raised price targets, citing Natera's strong market share in oncology MRD testing and growth potential, despite the company currently being high-growth but loss-making.

https://www.timothysykes.com/news/natera-inc-ntra-news-2026_06_24/

Trending Today

BlackBerry Limited ($BB) Stock Forecast: Up 20.7% Today

Acuity Brands Inc. ($AYI) Stock Forecast: Up 17.7% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Down 5.1% Today

Academy Sports and Outdoors, Inc. ($ASO) Stock Forecast: Down 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.3% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 10.1% Today

Applovin Corporation ($APP) Stock Forecast: Down 5.3% Today

TJX Companies Inc. (The) ($TJX) Stock Forecast: Down 5.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 7.3% Today

Alibaba Group Holding Limited ($BABA) Stock Forecast: Down 5.4% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

29.04.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

04.05.2026 - NTRA Stock was up 5.4%

• The bullish movement in Natera's stock today can be attributed to the positive news of the company expanding its board of directors with oncology experts, Thomas Lynch and Eric Rubin. This move is seen as strengthening the company's capabilities in a sector where it has experienced significant growth.
• Additionally, the announcement of Natera expanding its operations in Austin with a new sequencing facility, expected to create 200 new jobs, likely boosted investor confidence in the company's future prospects and growth potential.
• The upgrade of Natera's rating to "Outperform" by Wolfe Research, despite concerns about insider selling, also contributed to the bullish sentiment surrounding the stock. The price target of $260.00 reflects a positive outlook on Natera's performance in the medical diagnostics industry.

04.05.2026 - NTRA Stock was up 5.0%

• The collaboration with CytoDyn in the colorectal cancer study has generated positive investor sentiment towards Natera's expertise in oncology, resulting in a bullish uptrend in the stock.
• The inclusion of oncology specialists on Natera's board of directors strengthens the company’s market position and enhances its standing in the realm of personalized medicine.
• Disclosures of a director receiving $425K in RSU equity and the president of clinical diagnostics selling shares have had a marginal effect on stock movement, but the enthusiasm surrounding the strategic collaboration outweighs these transactions.
• Natera's focus on utilizing molecular insights and real-world data to optimize treatment responses in colorectal cancer and other solid tumors underscores its dedication to advancing precision medicine and fostering growth in the oncology sector.

23.05.2026 - NTRA Stock was up 5.9%

• The bullish movement in NTRA stock today can be attributed to the positive news of NCCN updating its bladder cancer guidelines to recommend ctDNA-MRD testing using Signatera™ technology, a significant development that validates Natera's technology and is expected to drive adoption in oncology practices.
• Despite the positive news, there was a slight dip in the stock price (-1.13%) following a Form 4 filing and insider selling activity by a co-founder's family trusts. This could have caused some initial uncertainty among investors, leading to the minor decrease in stock value.
• The class action lawsuit against Natera regarding IVF genetic testing claims could have added some pressure on the stock, but the overall market sentiment seems to have been more influenced by the positive NCCN guideline update, overshadowing the legal challenges the company is facing.
• Investors should keep an eye on how Natera addresses the profitability challenges and maintains market confidence amidst legal disputes, while also capitalizing on the momentum gained from the NCCN endorsement for its Signatera technology.

24.05.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock today is a direct result of the positive development of receiving regulatory approval in Japan for its Signatera test, especially for colorectal cancer patients. This achievement opens up a new market for the company and demonstrates an increasing acceptance of its innovative molecular residual disease testing technology.
• The partnership with Pirche AG to combine pre-transplant immunological risk assessment with Natera's Prospera test has also attracted investor attention and reinforced confidence in Natera's position in the transplant diagnostics market, further elevating the stock's performance.
• Analysts have shown optimism towards Natera, with BTIG raising the price target for Natera shares to $270 in light of recent advancements such as the inclusion of Signatera in NCCN guidelines for muscle-invasive bladder cancer. These recommendations have contributed to the positive outlook on the company and its growth potential.
• In summary, Natera's robust stock performance today reflects its strategic progress in regulatory approvals and collaborations, highlighting the market's acknowledgment of its ongoing revenue growth potential and expansion into new diagnostic realms.

25.05.2026 - NTRA Stock was up 7.5%

• The bullish movement in NTRA stock today can be attributed to the strategic partnership announcement with Eledon Pharmaceuticals for the exclusive use of Natera's Prospera kidney transplant assessment test in a Phase 3 clinical trial. This collaboration not only validates the effectiveness of Natera's technology but also opens up a new avenue for revenue generation and market expansion.
• Additionally, the recent approval of Natera's Signatera MRD test for colorectal cancer in Japan and the NCCN endorsement for its bladder cancer test have further boosted investor confidence in the company's growth potential and market position in the oncology sector.
• The positive market sentiment is also reflected in analysts' Buy/Outperform ratings and raised price targets, indicating a strong outlook for Natera despite its current status as a high-growth but loss-making company. The endorsements and partnerships are likely to drive increased adoption of Natera's tests, leading to potential revenue growth in the near future.

28.04.2026 - NTRA Stock was up 5.1%

• Today's bullish movement in Natera's stock is likely linked to positive updates on its clinical trials and innovations in genetic testing technologies.
• Commencement of patient enrollment for early-stage breast cancer studies and progress in trials for breast cancer and bladder cancer treatments have contributed to increased investor confidence.
• Upgrades to the Panorama prenatal test and FDA approval for Signatera in bladder cancer demonstrate Natera's dedication to innovation and expanding its market reach.
• Despite concerns regarding insider selling and valuation risks, the favorable outcomes in Natera's clinical trials and testing capabilities appear to have had a stronger impact, resulting in an upsurge in the stock price.

02.05.2026 - NTRA Stock was down 5.3%

• The bearish movement in NTRA today could be attributed to the significant insider selling totaling $56.0 million in the last three months, raising concerns among investors about the company's future prospects.
• Despite an optimistic "Outperform" rating and a price target of $260.00, the overvaluation of Natera by 9.2% according to GF Value™ might have contributed to the downward pressure on the stock.
• The rejection of an appeal in the false-advertising dispute with Natera by the U.S. Supreme Court could have added uncertainty and legal risks to Natera's operations, impacting investor confidence in the stock.
• While Natera has announced positive developments such as enhanced prenatal testing and market expansion, the ongoing insider selling and legal disputes might have overshadowed these advancements, leading to the bearish market movement today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.